Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23179169)

1.

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.

Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T.

Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165. Epub 2012 Nov 22. Review.

2.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

3.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

4.

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A.

Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000. Review.

PMID:
22480339
5.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
6.

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Health Technol Assess. 2001;5(1):1-137. Review.

7.

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A.

Pharmacoeconomics. 2005;23(12):1271-82.

PMID:
16336020
8.

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Getsios D, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2007;25(12):997-1006. Review.

PMID:
18047386
9.

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.

Hartz S, Getsios D, Tao S, Blume S, Maclaine G.

BMC Neurol. 2012 Feb 8;12:2. doi: 10.1186/1471-2377-12-2.

10.

Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.

Wong CL, Bansback N, Lee PE, Anis AH.

Can J Neurol Sci. 2009 Nov;36(6):735-9.

PMID:
19960752
11.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

12.
13.
14.

The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.

Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S.

Eur J Health Econ. 2014 Nov;15(8):791-800. doi: 10.1007/s10198-013-0523-y. Epub 2013 Aug 9.

15.

A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.

Kirby J, Green C, Loveman E, Clegg A, Picot J, Takeda A, Payne E.

Drugs Aging. 2006;23(3):227-40. Review.

PMID:
16608378
16.
17.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

18.
19.

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.

Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G.

Curr Med Res Opin. 2007 May;23(5):1187-97.

PMID:
17519086
20.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk